APOL1风险变异与高血压相关CKD黑人患者蛋白尿发生及后续eGFR下降
在AASK试验480例无蛋白尿的高血压相关CKD黑人患者中,17%携带APOL1高危基因型。中位随访6.8年,高危组发生蛋白尿的风险是低危组的1.72倍(95%CI 1.27-2.32),独立于年龄、性别、 ancestry、基线eGFR、收缩压和治疗分组。蛋白尿发生后eGFR下降更快,但下降速率在高危与低危组间无显著差异。
要点
- APOL1高危基因型与高血压相关CKD黑人患者蛋白尿发生风险增加独立相关。
- 蛋白尿发生后eGFR下降加速,但下降速率不因APOL1风险状态而异。
- 除APOL1外,导致蛋白尿的其他因素可能额外驱动CKD进展。
核心结论
- 在已确诊中度CKD的黑人中,APOL1高危变异与蛋白尿发生风险增加相关。
- 蛋白尿发生后肾功能下降更快,但下降速率不因APOL1风险状态而异,提示除APOL1外其他因素驱动CKD进展。
研究设计与样本
- 利用Cox模型分析AASK试验中480例有APOL1基因分型且基线无蛋白尿的非洲裔美国参与者。
- 蛋白尿定义为尿蛋白与肌酐比值加倍至≥0.22 g/g肌酐。
- 中位随访6.8年,82例(17%)为APOL1高危基因型(2个等位基因),254例(53%)发生蛋白尿。
主要发现
- 基线平均eGFR在高危组较低危组更低(49.6 vs 53.2 ml/min per 1.73 m2,P=0.02),但中位蛋白尿相似(两组均为0.04 g/g肌酐,P=0.43)。
- 高危基因型个体发生蛋白尿的可能性是低危基因型的1.72倍(95%CI 1.27-2.32),独立于年龄、性别、祖先、基线eGFR、基线收缩压和随机治疗组。
- 蛋白尿发生后eGFR下降更快,但下降速率在高危与低危组间无显著差异。
临床怎么用
- 对高血压相关CKD黑人患者,APOL1高危基因型提示蛋白尿发生风险较高,应加强蛋白尿监测。
- 蛋白尿发生后需关注肾功能下降,但APOL1状态不影响下降速率,管理应针对其他进展因素。
局限性
- 研究基于AASK试验人群,结果外推需谨慎。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The natural history of kidney disease among blacks who carry the APOL1 high-risk variants varies, with only a subgroup progressing to ESRD. We aimed to determine whether the APOL1 risk variants are associated with incident proteinuria in the context of hypertension-attributed CKD, and whether subsequent kidney function decline after the onset of proteinuria differs by APOL1 risk status. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Using Cox models, we studied the association between APOL1 risk status and incident proteinuria (defined as a doubling of urine protein-to-creatinine ratio to a level ≥0.22 g/g creatinine) among African-American Study of Kidney Disease and Hypertension (AASK) trial participants with APOL1 genotyping and without proteinuria at baseline. RESULTS: Of the 480 participants in our study, 82 (17%) had the high-risk genotypes (2 alleles), and 254 (53%) developed proteinuria over a median follow-up of 6.8 years. At baseline, mean eGFR was lower in the APOL1 high-risk group compared with the low-risk group (0 or 1 allele; 49.6 versus 53.2 ml/min per 1.73 m2, respectively; P=0.02), but median proteinuria was similar (0.04 g/g creatinine for both groups; P=0.43). Individuals with the high-risk genotypes were 1.72-fold more likely to develop incident proteinuria compared with those with the low-risk genotypes (95% confidence interval, 1.27 to 2.32), independent of age, sex, ancestry, baseline eGFR, baseline systolic BP, and randomized treatment groups. Although eGFR declined faster after the onset of proteinuria, this rate did not differ significantly by APOL1 risk status. CONCLUSIONS: Among blacks with established moderate CKD, the APOL1 high-risk variants are associated with greater risk of incident proteinuria. After proteinuria onset, kidney function declines more rapidly but does not differ by APOL1 risk status. This suggests that factors that lead to proteinuria, beyond APOL1, may additionally drive CKD progression.
引用
- Chen TK, Tin A, Peralta CA, et al. APOL1 Risk Variants, Incident Proteinuria, and Subsequent eGFR Decline in Blacks with Hypertension-Attributed CKD. Clin J Am Soc Nephrol. 2017. PMID: 29051146. doi:10.2215/CJN.01180117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。